Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) ...

Recurring services and consumables, centralized high-throughput labs, automation, payer connectivity and outsourced testing support scale, efficiency and sustainable returns.Dublin, Oct. 16, 2026 ...

Translating Positive ctDNA and MRD Test Results Into Actionable Breast Cancer Management Strategies - Natera / Breast Cancer, ...

The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Natera's multi-cancer early ...

Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Chromosomal Microarray Reflex Testing Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global chromosomal microarray ...

Natera’s Multi-Cancer Early Detection Assay Receives FDA Breakthrough Designation, Targeting Screening Gaps / Breakthrough ...

Natera (NTRA) is back in focus after the US Food and Drug Administration granted Breakthrough Device designation to its multi ...

A $9.5M settlement resolves a lawsuit that alleged Natera failed to clearly inform patients of potential out-of-pocket costs ...

Natera is rated Sell, as its valuation is stretched, with perfect execution priced in, despite looming competitive threats.

Growth opportunities center on expanded genetic panels, telehealth-enabled regional access, lab automation, awareness campaigns and integration with hospital prenatal care.Dublin, Oct. 07, 2026 (GLOBE ...